Cancer NetworkOriginal article
<![CDATA[How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?]]>
Data ReadoutpositivedaratumumabPositive
AI Analysis
Summary
Experts discussed long-term MAIA and CEPHEUS trial data supporting daratumumab-based regimens in newly diagnosed multiple myeloma, reinforcing its clinical utility in this patient population.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Long-term MAIA and CEPHEUS trial data discussed; data reinforce daratumumab-based regimens in newly diagnosed multiple myeloma
Importance:5/10
Sentiment:
0.60
multiple myelomadaratumumablong-term dataMAIA trialCEPHEUS trialnewly diagnosedclinical conference
Related Companies
Read the original article
Published by Cancer Network on October 9, 2026 4:30 PM